首页 | 本学科首页   官方微博 | 高级检索  
   检索      


The greening of biotechnology: the growth of the US biotechnology industry
Institution:1. Illumina, Inc., 5200 Illumina Way, San Diego 92122 CA, USA.;1. Univesity of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal;2. Research Unit on Governance,Competitiveness and Public Policies (GOVCOPP), DEGEIT, Univesity of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal;3. Research Center in Business and Economics (CICEE), Universidade Autónoma de Lisboa, Rua Sta. Marta 47, 5.º Andar, 1150-293 Lisboa, Portugal;3. ISCET-High Institute of Business Sciences and Tourism, Rua de Cedofeita, 285, 4050-180 Porto, Portugal
Abstract:The growth and advancement of biotechnology worldwide has been the focus of many studies, and at the heart of this advancement has been a new industry of small biotechnology firms in the United States. Since the early 1970s more than 300 small companies have been founded in the United States to work with the new technologies of genetic engineering, monoclonal antibody production, and in related areas. In addition, many major corporations in the United States have sought entry into biotechnology. Hundreds of new companies have been founded to interact with the biotechnology firms and large corporations, supplying reagents, equipment, fermentation expertise and serving a variety of other ancillary functions. Nowhere else in the world has a biotechnology industry been initiated to such a large degree. Today, the average US biotechnology firm is six to seven years old. The current state of the US biotechnology industry, historical perspectives, major trends and some future outlooks will be described below.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号